Aarey Drugs & Pharmaceuticals

63.51
+1.55
(2.50%)
ann
There are new updates from the company21 hours ago
Viewcross
right
Market Cap
180.08 Cr
EPS
1.84
PE Ratio
43.37
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
74.80
52 Week Low
31.35
PB Ratio
1.26
Debt to Equity
0.28
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,667.60
#1 4,00,113.10
34.75
#1 49,887.20
12.06
#1 9,648
-18.99
42.18
6,528.50
1,73,311.16
79.56
8,184.00
0.89
1,600
23.05
52.55
1,501.10
1,21,231.08
23.02
26,520.70
14.17
4,155
30.28
51.93
1,337.90
1,11,641.78
19.74
28,905.40
12.36
5,578
21.14
65.61
3,213.50
1,08,759.44
55.77
10,785.70
11.59
1,656
10.91
46.58
972.00
97,805.94
20.79
19,831.50
13.82
3,831
-0.19
60.87
2,312.10
95,392.28
47.96
10,615.60
19.57
1,942
-10.91
35.82
1,926.20
87,938.92
26.87
20,141.50
#1 19.94
1,936
#1 112.49
40.99
31,720.00
67,402.79
47.34
6,097.20
10.80
1,201
27.83
54.74
1,110.50
64,498.02
#1 18.56
29,559.20
17.55
3,169
-0.50
38.46
Forecast
Actual
Growth Rate
Revenue Growth
-4.53 %
Net Income Growth
23.68 %
Cash Flow Change
-133.59 %
ROE
9.97 %
ROCE
-1.39 %
EBITDA Margin (Avg.)
14.52 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
216
249
399
353
359
307
355
495
422
403
484
Expenses
212
245
386
342
347
297
344
481
411
391
472
EBITDA
4
4
13
11
12
10
12
14
11
11
12
Operating Profit %
1 %
0 %
2 %
2 %
2 %
1 %
1 %
2 %
2 %
1 %
0 %
Depreciation
1
1
1
1
1
1
1
2
2
2
2
Interest
2
2
4
2
2
2
2
2
3
4
4
Profit Before Tax
1
2
8
8
9
7
8
10
6
5
6
Tax
0
1
3
2
2
1
2
4
2
1
2
Net Profit
1
1
6
6
7
6
7
7
4
5
4
EPS in ₹
0.65
0.77
3.03
2.64
2.80
2.48
2.79
2.72
1.49
1.84
1.30

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
115
125
143
170
146
194
233
245
291
303
Fixed Assets
6
8
12
12
12
12
14
15
14
13
Current Assets
109
117
130
157
133
181
218
219
271
283
Capital Work in Progress
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
1
Other Assets
109
117
130
157
133
181
218
230
277
289
Total Liabilities
115
125
143
170
146
194
233
245
291
303
Current Liabilities
80
88
92
88
58
100
131
127
168
167
Non Current Liabilities
0
0
2
1
2
2
3
5
6
4
Total Equity
35
37
49
80
87
92
99
114
117
133
Reserve & Surplus
19
20
30
55
61
67
73
86
87
100
Share Capital
17
17
18
23
23
23
23
25
25
28

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-1
2
-1
2
-3
0
0
-1
1
1
Investing Activities
-2
-3
-5
-1
-1
-1
-3
-3
0
-2
Operating Activities
3
6
1
-20
1
3
6
1
-1
-3
Financing Activities
-2
-2
4
23
-3
-2
-3
2
1
6

Share Holding

% Holding
Mar 2021
Jun 2021
Jul 2021
Sept 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
49.38 %
49.38 %
49.38 %
49.38 %
48.05 %
48.05 %
48.06 %
50.03 %
50.03 %
50.03 %
50.04 %
50.04 %
50.04 %
50.04 %
45.28 %
45.28 %
45.44 %
44.80 %
44.80 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.40 %
3.40 %
2.75 %
2.34 %
2.34 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
37.15 %
40.16 %
40.14 %
40.44 %
42.40 %
42.23 %
43.30 %
42.48 %
42.25 %
42.41 %
42.24 %
42.15 %
40.61 %
41.14 %
47.14 %
44.51 %
47.56 %
44.87 %
45.79 %
Others
13.46 %
10.46 %
10.47 %
10.18 %
9.54 %
9.72 %
8.63 %
7.48 %
7.71 %
7.55 %
7.72 %
7.81 %
9.35 %
8.82 %
4.18 %
6.82 %
4.25 %
7.99 %
7.07 %
No of Share Holders
10,688
12,828
13,731
13,158
13,150
13,658
17,565
17,777
17,649
17,785
17,699
17,538
16,086
15,269
16,821
16,179
16,676
16,288
16,257

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 53.29 53.80
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 47.74 46.20
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 64.76 58.47
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 71.53 70.94
29 Dec 2023 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Dec 2023 44.60 49.15
29 Dec 2023 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
29 Dec 2023 44.60 49.15

Announcements

Closure of Trading Window21 hours ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 03, 2025
Reg. 33 - Audited Financial Results For The Quarter & Financial Year Ended 31St March 2025May 30, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday I.E 30Th May 2025May 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Announcement under Regulation 30 (LODR)-AllotmentMay 23, 2025
Board Meeting Intimation for Board Meeting IntimationMay 22, 2025
Reg 30 Of SEBI LODRMay 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Clarification On Price MovementApr 09, 2025
Clarification sought from Aarey Drugs & Pharmaceuticals LtdApr 07, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 06, 2025
Appointment of Company Secretary and Compliance OfficerMar 06, 2025
Board Meeting Outcome for Intimation Regarding Appointment Of Company Secretary And Compliance Officer Of The Company Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 06, 2025
Integrated Filing (Financial)Feb 17, 2025
Unaudited Financial Result For December 2024Feb 14, 2025
Board Meeting Outcome for OutcomeFeb 14, 2025
Board Meeting Intimation for Quarterly Financial ResultFeb 06, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Announcement under Regulation 30 (LODR)-Change in RTAJan 08, 2025
Announcement under Regulation 30 (LODR)-CessationJan 02, 2025
Board Meeting Outcome for OutcomeJan 02, 2025
Shareholder Meeting / Postal Ballot-Outcome of EGMJan 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 30, 2024
CorrigendumDec 27, 2024
Reg 30 Notice Of General MeetingDec 06, 2024
EGM NoticeDec 06, 2024
Announcement under Regulation 30 (LODR)-Meeting UpdatesDec 04, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementDec 04, 2024
Announcement under Regulation 30 (LODR)-Preferential IssueDec 04, 2024
Board Meeting Outcome for OutcomeDec 04, 2024
Closure of Trading WindowNov 29, 2024
Board Meeting Intimation for Raising Funds By Way Of Preferential Issue Of Shares Or Warrants Or Any Other MethodNov 29, 2024
Board Meeting Outcome for OutcomeNov 29, 2024
Closure of Trading WindowNov 26, 2024
Board Meeting Intimation for Fund RaisingNov 26, 2024
Financial Result For September 2024Nov 14, 2024
Board Meeting Outcome for OutcomeNov 14, 2024
Board Meeting Intimation for Financial Result For September 2024Nov 06, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024
Announcement under Regulation 30 (LODR)-AllotmentOct 01, 2024
Board Meeting Outcome for OutcomeOct 01, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Board Meeting Intimation for AllotmentSep 25, 2024
Closure of Trading WindowSep 24, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 10, 2024
Reg 30 For AGMSep 06, 2024
Book ClosureSep 06, 2024

Technical Indicators

RSI(14)
Neutral
69.25
ATR(14)
Volatile
3.00
STOCH(9,6)
Neutral
69.02
STOCH RSI(14)
Overbought
94.62
MACD(12,26)
Bullish
0.60
ADX(14)
Weak Trend
16.95
UO(9)
Bearish
62.47
ROC(12)
Uptrend And Accelerating
12.27
WillR(14)
Overbought
-4.95